Cargando…

Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism

BACKGROUND: Venous thromboembolism (VTE) is a life-threatening cardiovascular syndrome that characterized by the imbalance of hemostasis and thrombosis and the formation of thrombi in the blood vessels. The aim of this study was to elucidate the clinical impact of the PAI-1 4G/5G polymorphism in Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ziran, Kong, Lingjun, Luo, Guoju, Zhang, Han, Sun, Fengchun, Liang, Wenjuan, Wu, Wei, Guo, Zijian, Zhang, Rui, Dou, Yaling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662119/
https://www.ncbi.nlm.nih.gov/pubmed/36376889
http://dx.doi.org/10.1186/s12959-022-00430-x
_version_ 1784830623963152384
author Wang, Ziran
Kong, Lingjun
Luo, Guoju
Zhang, Han
Sun, Fengchun
Liang, Wenjuan
Wu, Wei
Guo, Zijian
Zhang, Rui
Dou, Yaling
author_facet Wang, Ziran
Kong, Lingjun
Luo, Guoju
Zhang, Han
Sun, Fengchun
Liang, Wenjuan
Wu, Wei
Guo, Zijian
Zhang, Rui
Dou, Yaling
author_sort Wang, Ziran
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is a life-threatening cardiovascular syndrome that characterized by the imbalance of hemostasis and thrombosis and the formation of thrombi in the blood vessels. The aim of this study was to elucidate the clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with VTE. METHODS: A total of 169 subjects (89 VTE, 10 hyperbilirubinemia, 10 hyperlipidemia and 60 healthy controls) were recruited at Peking Union Medical College Hospital. The accuracy of the TaqMan-MGB RT-PCR method for detecting F5 G1691A (FVL) and PAI-1 4G/5G polymorphisms was evaluated by using sequencing method as the gold standard. Besides, the association of the PAI-1 4G/5G polymorphism with susceptibility, treatment efficacy and recurrence status of VTE in Chinese population were explored. Eventually, the plasma PAI-1 antigen levels and PAI-1 4G/5G polymorphisms were determined on additional 64 subjects (32 VTE and 32 healthy controls) simultaneously. RESULTS: The TaqMan-MGB RT-PCR method was proven to be highly accurate in determining the FVL and PAI-1 4G/5G polymorphisms without interference from bilirubin and lipids in the samples. No obvious correlation of the PAI-1 4G/5G polymorphism with VTE was observed in our study by using five genetic models (allele, genotype, dominant, recessive and additive). Additionally, we also observed that individuals with the 4G/5G genotype had lower neutrophil counts and neutrophil-to-lymphocyte ratio (NLR) than the 5G/5G genotype. Furthermore, we found that the patients with the 5G/5G genotype were more likely to achieve complete recanalization compared to the 4G/4G genotype. In addition, individuals carrying the 5G/5G genotype were more likely to develop a recurrence-free status as compared to individuals with the 4G/4G or 4G/5G genotypes. PAI-1 antigen levels in the VTE group were significantly higher than those in the HC group. However, there was no significant difference in the antigen levels of PAI-1 among subjects carrying various genotypes in the VTE group or HC group. CONCLUSION: The PAI-1 4G/5G polymorphism has potential value in assessing the prognosis of Chinese patients with VTE. Our study has laid the foundation for the application of PAI-1 4G/5G polymorphism in the personalized management and monitoring of patients with VTE.
format Online
Article
Text
id pubmed-9662119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96621192022-11-14 Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism Wang, Ziran Kong, Lingjun Luo, Guoju Zhang, Han Sun, Fengchun Liang, Wenjuan Wu, Wei Guo, Zijian Zhang, Rui Dou, Yaling Thromb J Research BACKGROUND: Venous thromboembolism (VTE) is a life-threatening cardiovascular syndrome that characterized by the imbalance of hemostasis and thrombosis and the formation of thrombi in the blood vessels. The aim of this study was to elucidate the clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with VTE. METHODS: A total of 169 subjects (89 VTE, 10 hyperbilirubinemia, 10 hyperlipidemia and 60 healthy controls) were recruited at Peking Union Medical College Hospital. The accuracy of the TaqMan-MGB RT-PCR method for detecting F5 G1691A (FVL) and PAI-1 4G/5G polymorphisms was evaluated by using sequencing method as the gold standard. Besides, the association of the PAI-1 4G/5G polymorphism with susceptibility, treatment efficacy and recurrence status of VTE in Chinese population were explored. Eventually, the plasma PAI-1 antigen levels and PAI-1 4G/5G polymorphisms were determined on additional 64 subjects (32 VTE and 32 healthy controls) simultaneously. RESULTS: The TaqMan-MGB RT-PCR method was proven to be highly accurate in determining the FVL and PAI-1 4G/5G polymorphisms without interference from bilirubin and lipids in the samples. No obvious correlation of the PAI-1 4G/5G polymorphism with VTE was observed in our study by using five genetic models (allele, genotype, dominant, recessive and additive). Additionally, we also observed that individuals with the 4G/5G genotype had lower neutrophil counts and neutrophil-to-lymphocyte ratio (NLR) than the 5G/5G genotype. Furthermore, we found that the patients with the 5G/5G genotype were more likely to achieve complete recanalization compared to the 4G/4G genotype. In addition, individuals carrying the 5G/5G genotype were more likely to develop a recurrence-free status as compared to individuals with the 4G/4G or 4G/5G genotypes. PAI-1 antigen levels in the VTE group were significantly higher than those in the HC group. However, there was no significant difference in the antigen levels of PAI-1 among subjects carrying various genotypes in the VTE group or HC group. CONCLUSION: The PAI-1 4G/5G polymorphism has potential value in assessing the prognosis of Chinese patients with VTE. Our study has laid the foundation for the application of PAI-1 4G/5G polymorphism in the personalized management and monitoring of patients with VTE. BioMed Central 2022-11-14 /pmc/articles/PMC9662119/ /pubmed/36376889 http://dx.doi.org/10.1186/s12959-022-00430-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Ziran
Kong, Lingjun
Luo, Guoju
Zhang, Han
Sun, Fengchun
Liang, Wenjuan
Wu, Wei
Guo, Zijian
Zhang, Rui
Dou, Yaling
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title_full Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title_fullStr Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title_full_unstemmed Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title_short Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
title_sort clinical impact of the pai-1 4g/5g polymorphism in chinese patients with venous thromboembolism
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662119/
https://www.ncbi.nlm.nih.gov/pubmed/36376889
http://dx.doi.org/10.1186/s12959-022-00430-x
work_keys_str_mv AT wangziran clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT konglingjun clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT luoguoju clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT zhanghan clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT sunfengchun clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT liangwenjuan clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT wuwei clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT guozijian clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT zhangrui clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism
AT douyaling clinicalimpactofthepai14g5gpolymorphisminchinesepatientswithvenousthromboembolism